Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 23 May 2017
At a glance
- Drugs Romiplostim (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 16 May 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2020.
- 02 Mar 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2020.